T h e ne w e ngl a nd jou r na l o f m e dicine A TP citrate lyase is an enzyme in the cholesterol-biosynthesis pathway located upstream of 3-hydroxy-3-methylglutarylcoenzyme A reductase (HMGCR). 1 Inhibition of ATP citrate lyase should therefore reduce the plasma low-density lipoprotein (LDL) cholesterol level by interfering with the same pathway as inhibition of HMGCR with a statin; thus, ATP citrate lyase is an emerging target for pharmacotherapy. It is unclear whether lowering LDL cholesterol levels by inhibiting ATP citrate lyase will reduce the risk of cardiovascular events to the same extent as inhibiting HMGCR with a statin.
Bempedoic acid is an oral ATP citrate lyase inhibitor that has been shown in randomized trials of approximately 12 weeks' duration to reduce LDL cholesterol levels by up to 30% when used alone and by up to 50% in combination with ezetimibe. [2] [3] [4] In the Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen (CLEAR) Harmony trial, the results of which are reported in this issue of the Journal, 5 the difference between bempedoic acid and placebo at 12 weeks with respect to the change from baseline in the LDL cholesterol level was 18.1 percentage points in patients who were already receiving high-or moderate-intensity statin therapy. Although the incidence of cardiovascular events in that trial was lower among patients who received bempedoic acid than among those who received placebo, there was also a greater number of deaths from cardiovascular disease and cancer among participants who received the intervention; this raises the question of whether the inhibition of ATP citrate lyase by bempedoic acid or by another drug could be harmful. However, the trial was not designed to detect significant differences in the incidence of major adverse cardiac events or other outcomes.
We sought to estimate the clinical effect of lowering plasma LDL cholesterol levels through inhibition of ATP citrate lyase by comparing variants in ACLY that mimic the effect of an ATP citrate lyase inhibitor with variants in HMGCR that mimic the effect of a statin. Because bempedoic acid is likely to be used in combination with statins or ezetimibe, we also evaluated the effect of ACLY variants in combination with variants in HMGCR and NPC1L1 (Niemann-Pick C1-like 1), which encode proteins targeted by statins and ezetimibe, respectively. This approach has been used to accurately anticipate the results of several randomized trials that have evaluated other lipidlowering therapies. [6] [7] [8] [9] The objective of our study was to provide a biologic context for interpreting the results of the completed trials of ATP citrate lyase inhibitors, inform the design of future trials of ATP citrate lyase inhibitors, and anticipate, at least partially, the expected clinical effect of inhibition of ATP citrate lyase.
Me thods

Study Population
The study included 470,478 participants with individual-level data, including 367,641 participants who were enrolled in the U.K. Biobank study and 102,837 participants who were enrolled in one of the 14 prospective cohort or case-control studies as part of the Database of Genotypes and Phenotypes program of the National Center for Biotechnology Information. The study also included 184,305 participants enrolled in one of the 48 prospective cohort, case-control, or cross-sectional studies included the Coronary Artery Disease Genomewide Replication and Meta-Analysis plus the Coronary Artery Disease (CARDIoGRAMplusC4D) consortium and 159,208 participants enrolled in one of the 18 studies included in the Diabetes Genetics Replication and Meta-Analysis (DIAGRAM) consortium for whom summary-level data were available. [10] [11] [12] [13] Written informed consent was obtained from all the participants in each of the contributing studies. A description of the included studies and the genotyping platforms that were used in each study is provided in Table S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org.
Genetic Instruments
We constructed the genetic score for ACLY by combining all variants within ACLY (and also within 500 kb on either side of it) that were associated with plasma LDL cholesterol levels at a level of significance of less than 0.05, conditional on all other variants included in the score, and that were in low linkage disequilibrium (r 2 <0.3). 14, 15 Of the two alternative ACLY variants (or alleles) at each locus, the exposure allele was defined as the allele associated with a lower plasma LDL cholesterol level. 15, 16 For each study participant, we calculated an ACLY genetic score by adding the number of LDL cholesterol-lowering alleles that he or she had inherited at each variant that was included in the ACLY score, weighted by the conditional effect of each variant on plasma LDL cholesterol levels measured in milligrams per deciliter. For comparison, we also constructed genetic scores for HMGCR and NPC1L1, which encode proteins targeted by statins and ezetimibe, respectively, as previously described. [6] [7] [8] 
Study Outcomes
The primary efficacy outcome for the study was major cardiovascular events (defined as a composite of the first occurrence of myocardial infarction, coronary revascularization, ischemic stroke, or coronary death). The key secondary outcome was myocardial infarction. The primary safety outcome was any type of cancer, and the key secondary safety outcome was diabetes. Changes in plasma lipid levels, lipoprotein levels, and the lipoprotein particle concentration were used to compare the lipidomic signatures of the ACLY and HMGCR scores. A description of the data used in each analysis is provided in Table S2 in the Supplementary Appendix.
Study Design and Oversight
The primary analysis measured the association between the ACLY score and changes in plasma lipid levels, lipoprotein levels, and the risk of major cardiovascular events. To assess for an effect modification between ATP citrate lyase inhibition and either HMGCR or NPC1L1 inhibition, we measured the association between the ACLY genetic score and plasma lipoprotein levels and the risk of major cardiovascular events stratified according to the HMGCR and NPC1L1 genetic scores, respectively. To evaluate the combined effect of ATP citrate lyase inhibition with either HMGCR or NPC1L1 inhibition, we evaluated the combined association of the ACLY and HMGCR or NPC1L1 scores with changes in plasma lipid levels, lipoprotein levels, and the risk of major cardiovascular events using a two-by-two factorial mendelian randomization analysis. [6] [7] [8] [9] Although this study was funded by the manufacturer of bempedoic acid, the sponsor had no access to the data; had no role in the design, conduct, or analysis of the study; had no role in the drafting of the manuscript or its content; and did not participate in the decision to submit the manuscript for publication.
Statistical Analysis
We estimated the association of each genetic score with continuous outcomes, including plasma lipid and lipoprotein levels, using linear regression, and we estimated the association of each genetic score with the risk of major cardiovascular events and other dichotomous outcomes using logistic regression. All regression analyses were performed separately in each of the included studies with adjustment for age, sex, and the first five principal components of ancestry for participants with individual-level data, or with the ratio of effect estimates method for studies that provided summary-level data. These effect estimates were then combined across studies in a fixed-effects inverse-variance-weighted meta-analysis to produce summary estimates of effect with the use of a previously reported method that accounts for correlation among variants included in a genetic score. 17 To compare the association of the genetic scores with changes in plasma lipoprotein levels and the risk of cardiovascular events, we adjusted each effect-size estimate to scale the results for a standard decrement of 10 mg per deciliter (0.26 mmol per liter) in the LDL cholesterol level.
All analyses were performed with the use of Stata software, version 14 (StataCorp), R software, version 3.2.2 (R Foundation for Statistical Computing), and SNP & Variation Suite software, version 8.1.4 (Golden Helix). A detailed description of the methods, including a description of both mendelian randomization and factorial mendelian randomization, is provided in the Methods section in the Supplementary Appendix.
R esult s
Participant Characteristics
A total of 654,783 participants, including 105,429 participants who had a major cardiovascular event, were included in the efficacy analysis. A total of 656,895 participants, including 37,994 participants who had cancer and 53,145 participants who had diabetes, were included in the safety analysis. Individual participant-level data were available for 470,478 participants, including 44,628 participants who had a major cardiovascular event, 26,646 participants who had cancer, and 26,469 participants who had diabetes ( Table 1 ). The mean age among all 654,783 participants was 62.8 years, and 51.4% were women.
Genetic Scores
Nine independently inherited variants were included in the ACLY score, six in the HMGCR score, and five in the NPC1L1 score (Tables S3 through  S8 in the Supplementary Appendix). Although each variant included in the ACLY score was only weakly conditionally associated with plasma LDL cholesterol levels, the ATP citrate lyase score was robustly associated with LDL cholesterol levels. A 1-unit increase in the ACLY score was associated with an inverse-variance-weighted mean decrease of 1.21 mg per deciliter (95% confidence interval [CI], 0.94 to 1.48; P = 1.6×10 −18 ) (0.03 mmol per liter; 95% CI, 0.02 to 0.04) in the plasma LDL cholesterol level and a concordant decrease of 1.00 mg per deciliter (95% CI, 0.77 to 1.23; P = 7.2×10 −17 ) in the plasma apolipoprotein B level. In additional analyses involving 65,976 participants with lipid traits measured with the use of nuclear magnetic resonance spectroscopy, the ACLY and HMGCR scores were associated with a similar pattern of changes in the concentration and lipid composition of plasma lipoproteins; this suggests that they lower plasma LDL cholesterol levels by affecting the same metabolic pathway (Fig. 1) .
Association of Genetic Scores with Cardiovascular Events
For each decrease of 10 mg per deciliter in the LDL cholesterol level, the ACLY score was associated with a decrease of 17.7% in the risk of major cardiovascular events (odds ratio, 0.823; 95% CI, 0.78 to 0.87; P = 4.0×10 −14 ) and a 19.4% decrease in the risk of myocardial infarction (odds ratio, 0.806; 95% CI, 0.76 to 0.86; P = 6.4×10 −12 ). The association of the ACLY score was similar to the association of the HMGCR score with the risk of major cardiovascular events (odds ratio, 0.836; 95% CI, 0.81 to 0.87; P = 3.9×10 −19 ) and the risk of myocardial infarction (odds ratio, 0.827; 95% CI, 0.79 to 0.87; P = 2.6×10 −14 ) for each decrease of 10 mg per deciliter in the LDL cholesterol level. T
In addition, the ACLY and HMGCR genetic scores had similar associations with multiple different composite cardiovascular outcomes as well as with the individual components of those composite outcomes, including death from coronary heart disease ( Fig. 2A, and Table S9 in the Supplementary Appendix). Furthermore, the association of the ACLY score was also similar to the association of the scores for NPC1L1, proprotein convertase subtilisin-kexin type 9 (PCSK9), and the gene encoding the LDL receptor (LDLR) with the risk of major cardiovascular events for each decrease of 10 mg per deciliter in the LDL cholesterol level (Fig. 2B) .
Associations of Combined Genetic Scores with Lipids and Major Cardiovascular Events
The associations of the ACLY score with plasma apolipoprotein B levels and the risk of major cardiovascular events did not change in analyses stratified according to the HMGCR and NPC1L1 scores, respectively (Fig. 3A) . Furthermore, in twoby-two factorial mendelian randomization analyses, combined exposure to both the ACLY and HMGCR scores, as well as combined exposure to the ACLY and NPC1L1 scores, was associated with independent and linearly additive decreases in plasma LDL cholesterol and apolipoprotein B levels and corresponding independent and log-additive de-
Figure 2. Associations of the Genetic Scores with the Risk of Cardiovascular Events.
Panel A shows the association between the ACLY score and the risk of cardiovascular events per decrease of 10 mg per deciliter in the LDL cholesterol level, and Panel B shows the comparison of the association of the ACLY score and that of the other genetic scores with the risk of major cardiovascular events for the same decrease of 10 mg per deciliter in the LDL cholesterol level. Data on major cardiovascular events and myocardial infarctions are from analyses involving the total study sample of 654,783 participants; these analyses included both individual participantlevel and summary-level data. Data on major coronary events, coronary heart disease, coronary revascularization, and death from coronary heart disease are from the sample of 470,478 participants for whom individual-level data on these outcomes were available. Associations for all genetic scores are given for a standardized decrement of 10 mg per deciliter in the LDL cholesterol level. Boxes represent point estimates of effect, and lines 95% confidence intervals. Major coronary events were defined as the composite of nonfatal myocardial infarction, coronary revascularization, or death from coronary heart disease. Coronary heart disease was defined as the composite of nonfatal myocardial infarction or death from coronary heart disease, and coronary revascularization was defined as percutaneous coronary intervention or coronary-artery bypass grafting surgery. LDLR denotes LDL receptor, NPC1L1 NiemannPick C1-like 1, and PCSK9 proprotein convertase subtilisin-kexin type 9.
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A ACLY Score 1.0 0.9 creased risks of major cardiovascular events ( Fig. 3B and 3C ).
Proportional Effect Relative to Effect on LDL Cholesterol Level
Associations of ACLY and HMGCR Scores with Cancer and Other Adverse Outcomes
Neither the ACLY score nor the HMGCR score was associated with an increased risk of all cancers combined or any site-specific cancer (Table 2) . Although there was weak evidence that the ACLY score may have been associated with a decreased risk of lung cancer, this finding should be interpreted with caution because the associations between lung cancer and the ACLY score and between lung cancer and the HMGCR score did not differ significantly (Table 2 ). In contrast, the HMGCR, NPC1L1, PCSK9, and LDLR scores were associated with an increased risk of diabetes, but the ACLY score was not ( Table 2 , and Tables S10 through S12 in the Supplementary Appendix). T h e ne w e ngl a nd jou r na l o f m e dicine
Discussion
We found that variants in ACLY and HMGCR were associated with similar patterns of changes in the concentration and lipid composition of plasma lipoproteins and had a nearly identical effect on the risk of cardiovascular events for each unit decrease in the LDL cholesterol level. The results of our study thus confirm the mechanism by which ATP citrate lyase inhibition lowers plasma LDL cholesterol levels, and they provide validation for ATP citrate lyase inhibition as a genetic target. We also found that the lipidomic signature of LDL cholesterol-lowering ACLY variants was similar to that of LDL cholesterol-lowering HMGCR variants, which in turn are associated with a simi- * Effect sizes are presented as associations between either genetic score and the various outcomes standardized for a decrease of 10 mg per deciliter in the LDL cholesterol level. Analyses of cancer outcomes included 367,641 participants with individual-level data who were enrolled in the U.K. Biobank study. The analysis of lung cancer was supplemented with summary data from 27,209 participants (including 11,348 participants with lung cancer) who were enrolled in the International Lung Cancer Consortium. 19 Analyses of noncancer outcomes included 367,641 participants with individual-level data who were enrolled in the U.K. Biobank study. The analysis of diabetes risk is from a combined analysis involving 629,686 participants, including 470,478 participants with individual-level data from the U.K. Biobank and dbGAP studies and 159,208 participants with summary data from the DIAGRAM (Diabetes Genetics Replication and Meta-Analysis) consortium studies. 13 † The data shown are odds ratios, with the exception of change in blood pressure, which is an effect size. 20 This finding strongly implies that inhibiting ATP citrate lyase reduces plasma LDL cholesterol levels in the same way that inhibiting HMGCR with a statin reduces LDL cholesterol levels -that is, by reducing the concentration of LDL particles through up-regulation of the LDL receptor. Therefore, our study provides genetic validation for the proposed mechanism of action by which ATP citrate lyase inhibition reduces plasma LDL cholesterol levels. 1 In addition, our finding that ACLY variants associated with decreased LDL cholesterol levels are also associated with a decreased risk of cardiovascular events provides genetic validation for ATP citrate lyase as a therapeutic target. More relevant clinically, we found that genetic variants that mimic the effect of ATP citrate lyase inhibitors, statins, and ezetimibe, both alone and in combination, were all associated with similar effects on the risk of cardiovascular events per unit decrease in the LDL cholesterol level. Because longterm exposure to decreased LDL cholesterol levels associated with genetic variants that mimic the action of ATP citrate lyase inhibitors and statins has the same effect on the risk of cardiovascular events per unit decrease in the LDL cholesterol level, it is reasonable to assume that shorter-term pharmacologic reductions in LDL cholesterol levels due to treatment with an ATP citrate lyase inhibitor could have the same effect on the risk of cardiovascular events as treatment with a statin per unit decrease in the LDL cholesterol level. Therefore, we speculate that treatment with an ATP citrate lyase inhibitor, whether used alone or in combination with a statin or ezetimibe, would be likely reduce the risk of cardiovascular events by approximately 20% for each decrease of 39 mg per deciliter (1.0 mmol per liter) in the LDL cholesterol level. 21 This speculation assumes that an ATP citrate lyase inhibitor has no off-target effects; this is impossible to determine without large and long clinical trials.
Furthermore, we found that decreased LDL cholesterol levels associated with variants that mimic ATP citrate lyase inhibitors and statins had similar effects on multiple different cardiovascular events, including death from cardiovascular disease. Because randomized trials have shown that reducing LDL cholesterol levels with a statin reduces the risk of death from cardiovascular disease, 21 it is reasonable to assume that lowering LDL cholesterol levels with an ATP citrate lyase inhibitor could also reduce the risk of death from cardiovascular disease. Again, this assumption is based on the unknown side effects and off-target effects of such an inhibitor. In addition, because genetic variants that mimic the effect of ATP citrate lyase inhibitors appear to lower LDL cholesterol levels by the same mechanism of action as statins and because randomized trials have shown that treatment with a statin is not associated with an increased risk of cancer or death from cancer, it would seem reasonable to extrapolate that lowering LDL cholesterol levels with an ATP citrate lyase inhibitor would be unlikely to increase the risk of cancer. 22 In the specific case of bempedoic acid, we cannot rule out the possibility that a drug-specific effect of this agent, unrelated to its intended mechanism of action, increases the risk of death from cancer.
Our study has limitations. First, as mentioned, genetic variants that mimic the effect of a therapeutic agent cannot anticipate potential drugspecific adverse effects of a therapy that is not related to its mechanism of action (i.e., off-target effects). Second, genetic variants reflect the effect of lifelong exposure to a biomarker on an outcome and therefore cannot be used to estimate the expected effect of short-term pharmacologic changes in that biomarker directly. 9, 23, 24 Third, most major adverse effects tend to be uncommon, leading to imprecise estimates of effect, particularly with genetic variants that have small effects on the exposure of interest. As a result, evaluation of the association between a genetic variant that mimics the effect of a therapeutic agent and numerous potential adverse outcomes can lead to both spurious suggestions of increased risk and false reassurances of safety owing to potential off-target effects, imprecise estimates of effect, the play of chance related to multiple testing, and difficulties in translating the observed effect of lifelong exposure into the expected effect of short-term pharmacologic changes.
In conclusion, we found that genetic variants that mimic the effect of ATP citrate lyase inhibitors and statins appeared to lower plasma LDL cholesterol levels by the same mechanism of action. They were associated with nearly identical effects on the risk of cardiovascular disease and cancer per unit decrease in the LDL cholesterol level.
